Clinical trials: Degenerative; Dementia
Alzheimer Disease, Old Age; Dementia
Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)
The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the…
- Trial name
- BAD-GER (NCT07435467)
- Testing
- collection of blood samples
- Where
- 3 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Dementia, Frontotemporal
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
This is a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of VES001 in a two part followed by a…
- Trial name
- SORT-IN-1 (NCT06226064)
- Testing
- VES001
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Vesper Biotechnologies ApS
Essential Tremor, Parkinson Disease
Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders
The purpose of the research is to better understand the motor behavior of individuals in health and disease. The specific purpose of this project is to identify if we can utilize a smartphone to diagnose different movement…
- Conditions
- Essential Tremor, Parkinson Disease, Huntington Disease, Dystonia, Primary
- Trial name
- NCT04231487
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Rutgers, The State University of New Jersey
Familial Frontotemporal Dementia
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
This study is being done to learn more about normal thinking and behavior, mild thinking and behavior problems, Frontotemporal Dementia and other forms of dementia in families in which one or more relatives have a mutation…
- Trial name
- LEFFTDS (NCT02372773)
- Where
- 8 sites in United States, Canada
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Preclinical Alzheimer's Disease, Alzheimer Disease
Alzheimer's Tau Platform: Master Protocol
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late…
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Trial name
- ATP (NCT06957418)
- Testing
- AADvac1, Tau2
- Where
- 7 sites in United States
- Volunteers
- 900 people
- Sponsor
- Paul S. Aisen
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Neurodegenerative Disorders
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5).
- Trial name
- NCT00874783
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Alzheimer Disease, Mild Cognitive Impairment
Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
This study is being performed to generate data regarding brain vibration /oscillation differences between individuals with dementia and normal controls.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Frontotemporal Lobar Degeneration, Memory Disorders
- Trial name
- NCT02333942
- Testing
- Nautilus NeuroWaveTM System
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Dementia, Dementia Frontotemporal
Care Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and Emotions
The overall objective of this study is to compare knowledge, decisional conflict, preferences, and caregiver burden over time caregivers of Alzheimer's Disease and Related Dementias (ADRD) patients by comparing the effectiveness…
- Conditions
- Dementia, Dementia Frontotemporal, Dementia Alzheimers, Dementia, Mild
- Trial name
- NCT05165186
- Testing
- Video Intervention Arm
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Frontotemporal Lobar Degeneration
A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration
This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in…
- Trial name
- NCT00187525
- Testing
- Memantine
- Sponsor
- University of California, San Francisco
Alzheimer's Disease, Frontotemporal Dementia, Behavioral Variant
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
This pilot study aims to test clinical and connectivity changes following non-invasive stimulation of disease-specific networks in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NetCogBs (NCT03422250)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Alzheimer's Disease
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
This follow-up study continues to observe patients who have completed the phase 1 trial of AADvac1, for another 18 months. Long-term safety and behavior of the immune response to AADvac1 over time are the main points of interest.
- Trial name
- FUNDAMANT (NCT02031198)
- Testing
- AADvac1
- Where
- 4 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Axon Neuroscience SE
Memory Disorders, Alzheimer Disease
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
The proposed study is designed to evaluate the performance of the COGNISION™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment
- Trial name
- COGNISION™ (NCT00938665)
- Testing
- COGNISION™ System
- Where
- 7 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Neuronetrix, Inc.
Primary Progressive Aphasia
Language in Primary Progressive Aphasia
The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.
- Trial name
- NCT00537004
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Northwestern University
Dementia, Dementia, Vascular
The Care Ecosystem Consortium Effectiveness Study
The Care Ecosystem is an accessible, remotely delivered team-based dementia care model, designed to add value for patients, providers and payers in complex organizational and reimbursement structures.
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Alzheimers
- Trial name
- NCT05669365
- Testing
- Care Ecosystem
- Where
- 6 sites in United States
- Volunteers
- 1,227 people
- Sponsor
- University of California, San Francisco
Alzheimer's Disease (AD), Lewy Body Dementia (LBD)
Social-cognitive Functioning: Validation of a New Neuropsychological Test
It is now established that disturbances in social cognition are frequent in neurology and that they contribute to the development of social conduct disorders.
- Conditions
- Alzheimer's Disease (AD), Lewy Body Dementia (LBD), Frontotemporal Degeneration (FTD)
- Trial name
- REALSOCOG (NCT05558709)
- Testing
- REALSOCOG, BCS, Hetero-questionnaires
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Insomnia, Dementia
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team.
- Conditions
- Insomnia, Dementia, Frontotemporal Dementia
- Trial name
- NCT06093126
- Testing
- Lemborexant 5 MG
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Nova Scotia Health Authority
Dementia, Neuro-Degenerative Disease
Lived Experience Narratives in Dementia
The Lived Experience Narratives in Dementia (LEND) research programme involves five work packages (WP). WP1 explores how people living with dementia use narratives and how narratives can impact them.
- Conditions
- Dementia, Neuro-Degenerative Disease, Alzheimer Disease, Caregiver Burden
- Trial name
- LEND (NCT07757178)
- Testing
- Online LEND Intervention
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Alzheimer Disease
Effect of Lithium and Divalproex in Alzheimer's Disease
This study will examine the effect of the drugs lithium and divalproex (Depakote) on tau proteins, a type of protein in the brain and spinal fluid that are altered in patients with Alzheimer's disease.
- Trial name
- NCT00088387
- Testing
- Divalproex, Lithium
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)